Chronic Inflammatory Rheumatic Diseases of ChildhoodBOOST-RNCT07469787
Compassionate Care and Organization of Healthcare Services for a Successful Transition in Rheumatology
An observational study of Chronic Inflammatory Rheumatic Diseases of Childhood and Juvenile-Onset Chronic Inflammatory Rheumatic Diseases, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.
Trial summary
The transition from pediatric to adult care is a critical period for young people with chronic inflammatory rheumatic diseases (CIRD) and is associated with risks of poor self-management, loss to follow-up, and disease worsening. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Chronic Inflammatory Rheumatic Diseases of Childhood, Juvenile-Onset Chronic Inflammatory Rheumatic Diseases, Transition of Care in Chronic Inflammatory Rheumatic Diseases
- How many people
- 50 participants
- Where
- 1 siteFrance
- Study dates
- 26 Feb 2026to 26 Aug 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Young adults with a diagnosis of chronic inflammatory rheumatic disease previously followed in pediatric rheumatology, who transitioned to adult care after participating in a joint pediatric-adult transition consultation at Bicêtre Hospital between 2018 and 2024.
Who may be able to join
- Age 18 years or older
- Diagnosis of chronic inflammatory rheumatic disease
- Previously followed in pediatric rheumatology at Bicêtre Hospital
- Participation in a joint pediatric-adult transition consultation between 2018 and 2024
- Affiliated with a health insurance system
- No objection expressed to participation after being informed about the study
Who cannot join
- Patient lost to follow-up
- No participation in a joint pediatric-adult transition consultation
- Patient under guardianship, curatorship, or legal protection
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
CHU Bicêtre
Le Kremlin-Bicêtre
Perrine DUSSER, MD PhD, 145213146 ext. 0033, perrine.dusser@aphp.fr
About this study
The transition from pediatric to adult care is a critical period for young people with chronic inflammatory rheumatic diseases (CIRD) and is associated with risks of poor self-management, loss to follow-up, and disease worsening. Although structured transition programs have been recommended, real-world data on their effectiveness in rheumatology remain limited.
Since 2018, a structured transition program has been implemented at Bicêtre University Hospital (AP-HP, France), combining early transition preparation, a therapeutic patient education (TPE) workshop, and a joint pediatric-adult transition consultation. Some patients benefit from both components, while others receive a transition consultation only.
Read more
The BOOST-R study is a monocentric, non-interventional observational study designed to evaluate the impact of different transition modalities on self-management after transfer to adult care. The primary objective is to compare transition readiness, assessed using the validated French version of the Transition Readiness Assessment Questionnaire (TRAQ-FR), between patients who received a TPE workshop plus a transition consultation and those who received a transition consultation only.
Secondary objectives include evaluating continuity of care after transition, identifying factors associated with successful transition, assessing the contribution of the RESRIP support network, and describing patients who did not benefit from structured transition support.
Read the detailed description
The transition from pediatric to adult healthcare services represents a vulnerable period for adolescents and young adults with chronic inflammatory rheumatic diseases (CIRD). This phase is associated with increased risks of poor treatment adherence, disruption of follow-up, and adverse disease outcomes. While structured transition programs have been shown to improve patient autonomy and continuity of care, evidence in rheumatology remains limited, particularly regarding real-life effectiveness after transfer to adult care.
At Bicêtre University Hospital (AP-HP, France), a structured transition program has been progressively implemented since 2018 in collaboration with adult rheumatology and internal medicine departments. This program includes early transition information, progressive empowerment, a therapeutic patient education (TPE) workshop (MIRAJE program), and a joint pediatric-adult transition consultation. In parallel, some patients benefit from additional educational and administrative support provided by the RESRIP network after transition.
The BOOST-R study is a monocentric, observational, non-interventional study conducted in the pediatric rheumatology department of Bicêtre University Hospital. Adult patients with a diagnosis of CIRD who were followed in pediatric rheumatology and participated in a joint pediatric-adult transition consultation between 2018 and 2024 are eligible. Patients are contacted by postal mail and invited to complete an online questionnaire after receiving study information and having the opportunity to express non-opposition.
The primary outcome is transition readiness assessed using the French validated 20-item Transition Readiness Assessment Questionnaire (TRAQ-FR). The primary analysis compares the mean total TRAQ-FR score between patients who benefited from a TPE workshop plus a transition consultation and those who received a transition consultation only. Higher TRAQ-FR scores indicate better self-management and readiness for adult care.
Secondary outcomes include indicators of continuity of care after transition, such as number of adult care visits, delay to first adult visit, treatment adherence, and disease flares. Additional analyses will explore demographic, clinical, social, and educational factors associated with successful transition, evaluate the impact of support by the RESRIP network, and describe patients who did not benefit from structured transition interventions.
Statistical analyses will include descriptive analyses and multivariable regression models adjusted for relevant confounders, including age, sex, underlying disease, socio-professional status, and time since transition. Sensitivity analyses using propensity score methods will be performed to account for the non-randomized design.
The study involves no intervention and no additional risk for participants. Data are collected and managed in accordance with applicable French and European data protection regulations.
- Conditions
- Chronic Inflammatory Rheumatic Diseases of Childhood, Juvenile-Onset Chronic Inflammatory Rheumatic Diseases, Transition of Care in Chronic Inflammatory Rheumatic Diseases
- Keywords
- Continuity of care, Therapeutic patient education, Self-management, Transitional care, Pediatric to adult transition, Chronic inflammatory rheumatic diseases
What is being measured
The primary outcome is the main question the study is designed to answer.
Transition Readiness Assessment Questionnaire - French Version (TRAQ-FR) Total Score
Total score of the Transition Readiness Assessment Questionnaire - French version (TRAQ-FR).
The TRAQ-FR is a validated self-administered questionnaire assessing transition readiness in adolescents and young adults with chronic disease. It includes 20 items rated on a 5-point Likert scale (1-5).
The total score is calculated as the mean of completed items. Score range: 1 to 5. Higher scores indicate greater transition readiness (better outcome).
Measured: Baseline (at the time of questionnaire completion in 2026, corresponding to 1 to 8 years after transition depending on individual transition date)
Secondary outcomes (5)
Transition Readiness Assessment Questionnaire - French Version (TRAQ-FR) Domain Scores
Domain-specific scores of the TRAQ-FR, including: Medication management, Appointment keeping, Tracking health issues, Communication with healthcare providers, Managing daily activities, Each domain score is calculated as the mean of completed items within that domain.
Score range for each domain: 1 to 5. Higher scores indicate greater transition readiness.
Measured: Baseline (at the time of questionnaire completion in 2026)
Continuity of adult care within 12 months after transition
Proportion of patients who attended at least one adult specialist consultation within 12 months after their last pediatric visit.
Unit of measure: Percentage (%). Higher percentage indicates better continuity of care.
Measured: 12 months after transition
TRAQ-FR Total Score according to participation in structured transition support programs
Comparison of TRAQ-FR total score between patients who participated in a structured transition support program (therapeutic patient education and/or structured support network) and those who did not.
Score range: 1 to 5. Higher scores indicate greater transition readiness.
Measured: Baseline (at the time of questionnaire completion in 2026)
Continuity of adult care according to participation in structured transition support programs
Proportion of patients attending at least one adult specialist consultation within 12 months after transition, compared between patients with and without structured transition support.
Unit of measure: Percentage (%).
Measured: 12 months after transition
Successful transition defined by TRAQ-FR total score ≥4
Proportion of patients with a TRAQ-FR total score ≥4, considered indicative of high transition readiness.
Unit of measure: Percentage (%). Higher percentage indicates more successful transition.
Measured: Baseline (at the time of questionnaire completion in 2026)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Mar 2026
- Study start26 Feb 2026
- Primary completion26 Aug 2027 (estimated)
- Study completion26 Aug 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic Inflammatory Rheumatic Diseases of ChildhoodStudies of the same condition, open and under way.
- More trials run by Assistance Publique - Hôpitaux de ParisThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07469787
- Sponsor's protocol ID
- APHP251147
- Other IDs
- 2025-A01787-42
- Acronym
- BOOST-R
- Status last verified
- Jan 2026
- First submitted
- 9 Feb 2026
- Last updated
- 21 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Compassionate Care and Organization of Healthcare Services for a Successful Transition in Rheumatology
- ClinicalTrials.gov ID
- NCT07469787
- Acronym / sponsor ID
- BOOST-R / APHP251147
- Conditions
- Chronic Inflammatory Rheumatic Diseases of Childhood, Juvenile-Onset Chronic Inflammatory Rheumatic Diseases, Transition of Care in Chronic Inflammatory Rheumatic Diseases
- Keywords
- Continuity of care, Therapeutic patient education, Self-management, Transitional care, Pediatric to adult transition, Chronic inflammatory rheumatic diseases
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisUniversity, hospital or other
- Study start
- 26 Feb 2026 (actual)
- Primary completion
- 26 Aug 2027 (estimated)
- Study completion
- 26 Aug 2027 (estimated)
- First posted
- 13 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The transition from pediatric to adult care is a critical period for young people with chronic inflammatory rheumatic diseases (CIRD) and is associated with risks of poor self-management, loss to follow-up, and disease worsening. Although structured transition programs have been recommended, real-world data on their effectiveness in rheumatology remain limited.
Since 2018, a structured transition program has been implemented at Bicêtre University Hospital (AP-HP, France), combining early transition preparation, a therapeutic patient education (TPE) workshop, and a joint pediatric-adult transition consultation. Some patients benefit from both components, while others receive a transition consultation only.
The BOOST-R study is a monocentric, non-interventional observational study designed to evaluate the impact of different transition modalities on self-management after transfer to adult care. The primary objective is to compare transition readiness, assessed using the validated French version of the Transition Readiness Assessment Questionnaire (TRAQ-FR), between patients who received a TPE workshop plus a transition consultation and those who received a transition consultation only.
Secondary objectives include evaluating continuity of care after transition, identifying factors associated with successful transition, assessing the contribution of the RESRIP support network, and describing patients who did not benefit from structured transition support.
Detailed description
The transition from pediatric to adult healthcare services represents a vulnerable period for adolescents and young adults with chronic inflammatory rheumatic diseases (CIRD). This phase is associated with increased risks of poor treatment adherence, disruption of follow-up, and adverse disease outcomes. While structured transition programs have been shown to improve patient autonomy and continuity of care, evidence in rheumatology remains limited, particularly regarding real-life effectiveness after transfer to adult care.
At Bicêtre University Hospital (AP-HP, France), a structured transition program has been progressively implemented since 2018 in collaboration with adult rheumatology and internal medicine departments. This program includes early transition information, progressive empowerment, a therapeutic patient education (TPE) workshop (MIRAJE program), and a joint pediatric-adult transition consultation. In parallel, some patients benefit from additional educational and administrative support provided by the RESRIP network after transition.
The BOOST-R study is a monocentric, observational, non-interventional study conducted in the pediatric rheumatology department of Bicêtre University Hospital. Adult patients with a diagnosis of CIRD who were followed in pediatric rheumatology and participated in a joint pediatric-adult transition consultation between 2018 and 2024 are eligible. Patients are contacted by postal mail and invited to complete an online questionnaire after receiving study information and having the opportunity to express non-opposition.
The primary outcome is transition readiness assessed using the French validated 20-item Transition Readiness Assessment Questionnaire (TRAQ-FR). The primary analysis compares the mean total TRAQ-FR score between patients who benefited from a TPE workshop plus a transition consultation and those who received a transition consultation only. Higher TRAQ-FR scores indicate better self-management and readiness for adult care.
Secondary outcomes include indicators of continuity of care after transition, such as number of adult care visits, delay to first adult visit, treatment adherence, and disease flares. Additional analyses will explore demographic, clinical, social, and educational factors associated with successful transition, evaluate the impact of support by the RESRIP network, and describe patients who did not benefit from structured transition interventions.
Statistical analyses will include descriptive analyses and multivariable regression models adjusted for relevant confounders, including age, sex, underlying disease, socio-professional status, and time since transition. Sensitivity analyses using propensity score methods will be performed to account for the non-randomized design.
The study involves no intervention and no additional risk for participants. Data are collected and managed in accordance with applicable French and European data protection regulations.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Young adults with a diagnosis of chronic inflammatory rheumatic disease previously followed in pediatric rheumatology, who transitioned to adult care after participating in a joint pediatric-adult transition consultation at Bicêtre Hospital between 2018 and 2024.
Key inclusion criteria (6 listed)
- Age 18 years or older
- Diagnosis of chronic inflammatory rheumatic disease
- Previously followed in pediatric rheumatology at Bicêtre Hospital
- Participation in a joint pediatric-adult transition consultation between 2018 and 2024
- Affiliated with a health insurance system
Key exclusion criteria (3 listed)
- Patient lost to follow-up
- No participation in a joint pediatric-adult transition consultation
- Patient under guardianship, curatorship, or legal protection
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Transition Readiness Assessment Questionnaire - French Version (TRAQ-FR) Total Score
Time frame: Baseline (at the time of questionnaire completion in 2026, corresponding to 1 to 8 years after transition depending on individual transition date)
Total score of the Transition Readiness Assessment Questionnaire - French version (TRAQ-FR). The TRAQ-FR is a validated self-administered questionnaire assessing transition readiness in adolescents and young adults with chronic disease. It includes 20 items rated on a 5-point Likert scale (1-5). The total score is calculated as the mean of completed items. Score range: 1 to 5. Higher scores indicate greater transition readiness (better outcome).
5 secondary outcomes
Transition Readiness Assessment Questionnaire - French Version (TRAQ-FR) Domain Scores
Time frame: Baseline (at the time of questionnaire completion in 2026)
Continuity of adult care within 12 months after transition
Time frame: 12 months after transition
TRAQ-FR Total Score according to participation in structured transition support programs
Time frame: Baseline (at the time of questionnaire completion in 2026)
Continuity of adult care according to participation in structured transition support programs
Time frame: 12 months after transition
Successful transition defined by TRAQ-FR total score ≥4
Time frame: Baseline (at the time of questionnaire completion in 2026)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Apr 2026.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Chronic Inflammatory Rheumatic Diseases of Childhood and Juvenile-Onset Chronic Inflammatory Rheumatic Diseases, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 21 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Perrine DUSSER, MD PhD (145213146 ext. 0033, perrine.dusser@aphp.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Transition Readiness Assessment Questionnaire - French Version (TRAQ-FR) Total Score (time frame: Baseline (at the time of questionnaire completion in 2026, corresponding to 1 to 8 years after transition depending on individual transition date)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Apr 2026.